Latest & Greatest

Latest & Greatest

Recent developments in the field of hematology/oncology, including drug approvals, policy updates, and clinical trial results

First CAR T-Cell Therapy for Pediatric Leukemia Gains FDA Approval

The U.S. Food and Drug Administration (FDA) approved the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel for the treatment of pediatric and young adult...

Dasatinib Receives Priority Review for New CML Indications

The U.S. Food and Drug Administration (FDA) granted priority review to dasatinib, a tyrosine kinase inhibitor, for pediatric patients with chronic myeloid leukemia (CML). The...

FDA Approves Enasidenib for Patients With Relapsed/Refractory AML

The U.S. Food and Drug Administration (FDA) approved enasidenib, an isocitrate dehydrogenase-2 (IDH2) inhibitor, for adults with relapsed/refractory IDH2-mutated acute myeloid leukemia (AML). The...

Ibrutinib Becomes First FDA-Approved Therapy for Chronic GVHD

The U.S. Food and Drug Administration approved ibrutinib, a Bruton tyrosine kinase inhibitor, for secondline treatment of adults with chronic graft-versus-host disease (cGVHD), making...

FDA Approves Inotuzumab Ozogamicin for Patients With Relapsed/Refractory B-Cell Precursor ALL

The U.S. Food and Drug Administration (FDA) approved inotuzumab ozogamicin, an anti-CD22 monoclonal antibody, for adults with relapsed/refractory B-cell precursor acute lymphocytic leukemia (ALL). The...

Venetoclax Gets Breakthrough-Therapy Designation for AML

The FDA granted breakthrough-therapy designation to the BCL2 inhibitor venetoclax, in combination with cytarabine, for the treatment of older patients with treatment-naïve AML who...

Researchers Carry Out First Gene Editing of Embryos in the United States

A team of researchers at Oregon Health and Science University successfully used gene-editing technology to correct defective genes in a human embryo. This is...

President Declares State of Emergency After Urged by Federal Opioid Commission

On August 10, President Trump declared the opioid crisis a national emergency in response to a report from the Commission on Combating Drug Addiction...

FDA Approves First New Sickle Cell Therapy in Nearly 20 Years

The U.S. Food and Drug Administration approved L-glutamine oral powder for patients ≥5 years old with sickle cell disease (SCD). It is the first...

Eculizumab Associated With Increased Risk of Meningococcal Disease

A report from the Centers for Disease Control and Prevention (CDC) noted that eculizumab – a drug approved by the U.S. Food and Drug...
Advertisement

Current Issue

October 2017, Volume 3, Issue 12

This issue features a look at hospital ranking systems, the risks and benefits of opioids for pain management, and more.